Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2021

01-12-2021 | Severe Acute Respiratory Syndrome Coronavirus | Review

Virus infection induced pulmonary fibrosis

Authors: Wei Jie Huang, Xiao Xiao Tang

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Pulmonary fibrosis is the end stage of a broad range of heterogeneous interstitial lung diseases and more than 200 factors contribute to it. In recent years, the relationship between virus infection and pulmonary fibrosis is getting more and more attention, especially after the outbreak of SARS-CoV-2 in 2019, however, the mechanisms underlying the virus-induced pulmonary fibrosis are not fully understood. Here, we review the relationship between pulmonary fibrosis and several viruses such as Human T-cell leukemia virus (HTLV), Human immunodeficiency virus (HIV), Cytomegalovirus (CMV), Epstein–Barr virus (EBV), Murine γ-herpesvirus 68 (MHV-68), Influenza virus, Avian influenza virus, Middle East Respiratory Syndrome (MERS)-CoV, Severe acute respiratory syndrome (SARS)-CoV and SARS-CoV-2 as well as the mechanisms underlying the virus infection induced pulmonary fibrosis. This may shed new light on the potential targets for anti-fibrotic therapy to treat pulmonary fibrosis induced by viruses including SARS-CoV-2.
Literature
1.
Reynolds HY. Lung inflammation and fibrosis: an alveolar macrophage-centered perspective from the 1970s to 1980s. Am J Respir Crit Care Med. 2005;171(2):98–102.PubMed
2.
Han X, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. 2021;299(1):E177-e186.PubMed
3.
Yamagishi M, et al. HTLV-1-mediated epigenetic pathway to adult T-cell leukemia-lymphoma. Front Microbiol. 2018;9:1686.PubMedPubMedCentral
4.
Yamashiro T, et al. CT scans of the chest in carriers of human T-cell lymphotropic virus type 1: presence of interstitial pneumonia. Acad Radiol. 2012;19(8):952–7.PubMed
5.
6.
Kim SJ, et al. Transactivation of the transforming growth factor beta 1 (TGF-beta 1) gene by human T lymphotropic virus type 1 tax: a potential mechanism for the increased production of TGF-beta 1 in adult T cell leukemia. J Exp Med. 1990;172(1):121–9.PubMed
7.
Teruya H, et al. Human T-cell leukemia virus type I infects human lung epithelial cells and induces gene expression of cytokines, chemokines and cell adhesion molecules. Retrovirology. 2008;5:86.PubMedPubMedCentral
8.
Matsuyama W, et al. Influence of human T lymphotrophic virus type I on cryptogenic fibrosing alveolitis—HTLV-I associated fibrosing alveolitis: proposal of a new clinical entity. Clin Exp Immunol. 2003;133(3):397–403.PubMedPubMedCentral
9.
Miyazato A, et al. Chemokine synthesis and cellular inflammatory changes in lungs of mice bearing p40tax of human T-lymphotropic virus type 1. Clin Exp Immunol. 2000;120(1):113–24.PubMedPubMedCentral
10.
Doffman SR, Miller RF. Interstitial lung disease in HIV. Clin Chest Med. 2013;34(2):293–306.PubMed
11.
Crothers K, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183(3):388–95.PubMedPubMedCentral
12.
Leader JK, et al. Risk factors associated with quantitative evidence of lung emphysema and fibrosis in an HIV-infected cohort. J Acquir Immune Defic Syndr. 2016;71(4):420–7.PubMedPubMedCentral
13.
Marts LT, Guidot DM, Sueblinvong V. HIV-1 protein gp120 induces mouse lung fibroblast-to-myofibroblast transdifferentiation via CXCR4 activation. Am J Med Sci. 2019;357(6):483–91.PubMedPubMedCentral
14.
Pellicelli AM, et al. Pathogenesis of HIV-related pulmonary hypertension. Ann N Y Acad Sci. 2001;946:82–94.PubMed
15.
Sime PJ, et al. Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am J Pathol. 1998;153(3):825–32.PubMedPubMedCentral
16.
Warshamana GS, Corti M, Brody AR. TNF-alpha, PDGF, and TGF-beta(1) expression by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: tnf-alpha induces TGF-beta(1). Exp Mol Pathol. 2001;71(1):13–33.PubMed
17.
Meng Y, et al. Angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-κB pathway. Am J Respir Cell Mol Biol. 2014;50(4):723–36.PubMed
18.
Cook CH, et al. Pulmonary cytomegalovirus reactivation causes pathology in immunocompetent mice. Crit Care Med. 2006;34(3):842–9.PubMedPubMedCentral
19.
Cook CH, et al. Occult herpes family viral infections are endemic in critically ill surgical patients. Crit Care Med. 2003;31(7):1923–9.PubMed
20.
Balthesen M, Messerle M, Reddehase MJ. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol. 1993;67(9):5360–6.PubMedPubMedCentral
21.
Yonemaru M, et al. Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis. Eur Respir J. 1997;10(9):2040–5.PubMed
22.
Franquet T, Lee KS, Müller NL. Thin-section CT findings in 32 immunocompromised patients with cytomegalovirus pneumonia who do not have AIDS. AJR Am J Roentgenol. 2003;181(4):1059–63.PubMed
23.
Papazian L, et al. Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia. Anesthesiology. 1996;84(2):280–7.PubMed
24.
Li Y, et al. Latent cytomegalovirus infection exacerbates experimental pulmonary fibrosis by activating TGF-beta1. Mol Med Rep. 2016;14(2):1297–301.PubMed
25.
Walton KL, Johnson KE, Harrison CA. Targeting TGF-β mediated SMAD signaling for the prevention of fibrosis. Front Pharmacol. 2017;8:461.PubMedPubMedCentral
26.
She YX, Yu QY, Tang XX. Role of interleukins in the pathogenesis of pulmonary fibrosis. Cell Death Discov. 2021;7(1):52.PubMedPubMedCentral
27.
van de Berg PJ, et al. Cytomegalovirus infection reduces telomere length of the circulating T cell pool. J Immunol. 2010;184(7):3417–23.PubMed
28.
Duckworth A, et al. Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study. Lancet Respir Med. 2021;9(3):285–94.PubMed
29.
Ankermann T, et al. Chronic interstitial lung disease with lung fibrosis in a girl: uncommon sequelae of Epstein–Barr virus infection. Pediatr Pulmonol. 2003;35(3):234–8.PubMed
30.
Malizia AP, et al. Alveolar epithelial cell injury with Epstein–Barr virus upregulates TGFbeta1 expression. Am J Physiol Lung Cell Mol Physiol. 2008;295(3):L451–60.PubMed
31.
Sides MD, et al. The Epstein–Barr virus latent membrane protein 1 and transforming growth factor-beta1 synergistically induce epithelial–mesenchymal transition in lung epithelial cells. Am J Respir Cell Mol Biol. 2011;44(6):852–62.PubMed
32.
Krug LT, et al. Inhibition of NF-kappaB signaling reduces virus load and gammaherpesvirus-induced pulmonary fibrosis. Am J Pathol. 2010;177(2):608–21.PubMedPubMedCentral
33.
Mora AL, et al. Lung infection with gamma-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice. Am J Physiol Lung Cell Mol Physiol. 2005;289(5):L711–21.PubMed
34.
Mora AL, et al. Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice. Am J Respir Crit Care Med. 2007;175(11):1139–50.PubMedPubMedCentral
35.
Shieh WJ, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol. 2010;177(1):166–75.PubMedPubMedCentral
36.
Nakajima N, et al. Histopathological and immunohistochemical findings of 20 autopsy cases with 2009 H1N1 virus infection. Mod Pathol. 2012;25(1):1–13.PubMed
37.
Li P, et al. Serial evaluation of high-resolution CT findings in patients with pneumonia in novel swine-origin influenza A (H1N1) virus infection. Br J Radiol. 2012;85(1014):729–35.PubMedPubMedCentral
38.
Mineo G, et al. Post-ARDS pulmonary fibrosis in patients with H1N1 pneumonia: role of follow-up CT. Radiol Med. 2012;117(2):185–200.PubMed
39.
Saha A, et al. Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(1):85–90.PubMedPubMedCentral
40.
Wen Y, et al. Immunological features in patients with pneumonitis due to influenza A H1N1 infection. J Investig Allergol Clin Immunol. 2011;21(1):44–50.PubMed
41.
Shatskaya EV, et al. Study of SMAD-dependent signal pathway in the development of early pulmonary fibrosis in mice infected with influenza A/H1N1 virus. Bull Exp Biol Med. 2017;162(5):647–9.PubMed
42.
Drakopanagiotakis F, et al. Apoptosis in lung injury and fibrosis. Eur Respir J. 2008;32(6):1631–8.PubMed
43.
Roberson EC, et al. Influenza induces endoplasmic reticulum stress, caspase-12-dependent apoptosis, and c-Jun N-terminal kinase-mediated transforming growth factor-β release in lung epithelial cells. Am J Respir Cell Mol Biol. 2012;46(5):573–81.PubMedPubMedCentral
44.
Lu PX, et al. Radiological features of lung changes caused by avian influenza subtype A H5N1 virus: report of two severe adult cases with regular follow-up. Chin Med J. 2010;123(1):100–4.PubMed
45.
Chen C, Chen J, Huang JA. Persistence of lymphocytopenia with CT abnormalities among patients with critical H7N9 swine-origin influenza A virus infection. Jpn J Radiol. 2015;33(10):657–62.PubMedPubMedCentral
46.
Gao HN, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med. 2013;368(24):2277–85.PubMed
47.
To KF, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol. 2001;63(3):242–6.PubMed
48.
Huang JB, et al. Histopathological findings in a critically ill patient with avian influenza A (H7N9). J Thorac Dis. 2015;7(12):E672–7.PubMedPubMedCentral
49.
50.
Xu T, et al. Acute respiratory distress syndrome induced by avian influenza A (H5N1) virus in mice. Am J Respir Crit Care Med. 2006;174(9):1011–7.PubMed
51.
Anikina AG, et al. Expression of profibrotic growth factors and their receptors by mouse lung macrophages and fibroblasts under conditions of acute viral inflammation in influenza A/H5N1 virus. Bull Exp Biol Med. 2014;156(6):833–7.PubMed
52.
Zou Z, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. 2014;5:3594.PubMed
53.
Huang F, et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun. 2014;5:3595.PubMed
54.
Meng Y, et al. The angiotensin-converting enzyme 2/angiotensin (1–7)/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA/Rho kinase pathway. Antioxid Redox Signal. 2015;22(3):241–58.PubMedPubMedCentral
55.
Uhal BD, et al. Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1–7/Mas axis. Am J Physiol Lung Cell Mol Physiol. 2011;301(3):L269–74.PubMedPubMedCentral
56.
Kuba K, et al. Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. J Mol Med. 2006;84(10):814–20.PubMed
57.
58.
Ng DL, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of middle east respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol. 2016;186(3):652–8.PubMed
59.
Das KM, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging. 2017;27(3):342–9.PubMedPubMedCentral
60.
Zhou J, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis. 2014;209(9):1331–42.PubMed
61.
Zielecki F, et al. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J Virol. 2013;87(9):5300–4.PubMedPubMedCentral
62.
Yeung ML, et al. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. Nat Microbiol. 2016;1:16004.PubMedPubMedCentral
63.
Kim J, et al. Middle East respiratory syndrome-coronavirus infection into established hDPP4-transgenic mice accelerates lung damage via activation of the pro-inflammatory response and pulmonary fibrosis. J Microbiol Biotechnol. 2020;30(3):427–38.PubMed
64.
Falzarano D, et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 2014;10(8): e1004250.PubMedPubMedCentral
65.
66.
Tsui PT, et al. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg Infect Dis. 2003;9(9):1064–9.PubMedPubMedCentral
67.
68.
Hwang DM, et al. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol. 2005;18(1):1–10.PubMed
69.
Xie L, et al. Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge. Chest. 2005;127(6):2119–24.PubMed
70.
Hui DS, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60(5):401–9.PubMedPubMedCentral
71.
Zhang P, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 2020;8:8.PubMedPubMedCentral
72.
Xie L, et al. Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge. Respir Res. 2005;6:5.PubMedPubMedCentral
73.
Rockx B, et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol. 2009;83(14):7062–74.PubMedPubMedCentral
74.
Zhao X, Nicholls JM, Chen YG. Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-beta signaling. J Biol Chem. 2008;283(6):3272–80.PubMed
75.
76.
Courey AJ, et al. The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. Blood. 2011;118(8):2313–21.PubMedPubMedCentral
77.
Rana T, et al. PAI-1 regulation of TGF-β1-induced alveolar type II cell senescence, SASP secretion, and SASP-mediated activation of alveolar macrophages. Am J Respir Cell Mol Biol. 2020;62(3):319–30.PubMedPubMedCentral
78.
Page C, et al. Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection. J Virol. 2012;86(24):13334–49.PubMedPubMedCentral
79.
Gieseck RL 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2018;18(1):62–76.PubMed
80.
Grillo F, et al. Lung fibrosis: an undervalued finding in COVID-19 pathological series. Lancet Infect Dis. 2021;21(4):e72.PubMed
81.
Guan WJ, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.PubMed
82.
Yu M, et al. Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J Radiol. 2020;21(6):746–55.PubMedPubMedCentral
83.
84.
Lax SF, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome : results from a prospective, single-center clinicopathologic case series. Ann Intern Med. 2020;173(5):350–61.PubMed
85.
86.
Li X, et al. Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: a cohort study. Respir Res. 2021;22(1):203.PubMedPubMedCentral
87.
Pan Y, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020;30(6):3306–9.PubMed
88.
Zhang H, et al. Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. Ann Intern Med. 2020;172(9):629–32.PubMed
89.
Hu ZJ, et al. Lower circulating interferon-gamma is a risk factor for lung fibrosis in COVID-19 patients. Front Immunol. 2020;11: 585647.PubMedPubMedCentral
90.
91.
92.
Shan C, et al. Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques. Cell Res. 2020;30(8):670–7.PubMedPubMedCentral
93.
Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020;41(12):1100–15.PubMedPubMedCentral
94.
95.
Krishna Murthy P, et al. Repurposing of histone deacetylase inhibitors: a promising strategy to combat pulmonary fibrosis promoted by TGF-beta signalling in COVID-19 survivors. Life Sci. 2021;266: 118883.
96.
Chen G, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9.PubMedPubMedCentral
97.
Pedroza M, et al. STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. FASEB J. 2016;30(1):129–40.PubMed
98.
Xu J, et al. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Respir Res. 2020;21(1):182.PubMedPubMedCentral
99.
Leng L, et al. Pathological features of COVID-19-associated lung injury: a preliminary proteomics report based on clinical samples. Signal Transduct Target Ther. 2020;5(1):240.PubMedPubMedCentral
100.
Crisan-Dabija R, et al. “A chain only as strong as its weakest link”: an up-to-date literature review on the bidirectional interaction of pulmonary fibrosis and COVID-19. J Proteome Res. 2020;19(11):4327–38.PubMedPubMedCentral
101.
Chen X, et al. Coronavirus membrane-associated papain-like proteases induce autophagy through interacting with Beclin1 to negatively regulate antiviral innate immunity. Protein Cell. 2014;5(12):912–27.PubMedPubMedCentral
102.
103.
Campbell GR, et al. Human immunodeficiency virus type 1 Nef inhibits autophagy through transcription factor EB sequestration. PLoS Pathog. 2015;11(6): e1005018.PubMedPubMedCentral
104.
Chaumorcel M, et al. The human cytomegalovirus protein TRS1 inhibits autophagy via its interaction with Beclin 1. J Virol. 2012;86(5):2571–84.PubMedPubMedCentral
105.
Mouna L, et al. Analysis of the role of autophagy inhibition by two complementary human cytomegalovirus BECN1/Beclin 1-binding proteins. Autophagy. 2016;12(2):327–42.PubMed
106.
107.
Hill C, et al. Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. Cell Death Dis. 2019;10(8):591.PubMedPubMedCentral
108.
Zhao H, et al. Autophagy, an important therapeutic target for pulmonary fibrosis diseases. Clin Chim Acta. 2020;502:139–47.PubMed
109.
Diem K, et al. Mechanical stretch activates piezo1 in caveolae of alveolar type I cells to trigger ATP release and paracrine stimulation of surfactant secretion from alveolar type II cells. Faseb J. 2020;34(9):12785–804.PubMed
Metadata
Title
Virus infection induced pulmonary fibrosis
Authors
Wei Jie Huang
Xiao Xiao Tang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-03159-9

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue

Research

Gene signature and immune cell profiling by high-dimensional, single-cell analysis in COVID-19 patients, presenting Low T3 syndrome and coexistent hematological malignancies

Research

TRPC3, but not TRPC1, as a good therapeutic target for standalone or complementary treatment of DMD

Letter to the Editor

The effect of a newly developed mini-light-emitting diode catheter for interstitial photodynamic therapy in pancreatic cancer xenografts

Research

Heparin-binding growth factor (HDGF) drives radioresistance in breast cancer by activating the STAT3 signaling pathway

Research

Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice

Research

Increased risk of pulmonary and extrapulmonary tuberculosis infection in patients with polycystic kidney disease: a nationwide population-based study with propensity score-matching analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits